Venetoclax is a BCL-2-selective small-molecule inhibitor that is FDA-approved in combination with other agents for the treatment of adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or AML [24]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.